VAXGEN
VaxGen, Inc. operates as a biopharmaceutical company in the United States. It owns a biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that could be used to make cell culture or microbial biologic products.
VAXGEN
Industry:
Biotechnology
Founded:
1995-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.vaxgen.com
Total Employee:
1+
Status:
Active
Contact:
(650) 624-1000
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Google Font API Google Tag Manager Google Analytics Content Delivery Network LetsEncrypt SSL By Default Font Awesome Global Site Tag
Similar Organizations
Cimarron Medical
Cimarron Medical operates as a pre-clinical biopharmaceutical company in the United States.
Jenrin Discovery
Jenrin Discovery is a biopharmaceutical Company.
Stock Details
Official Site Inspections
http://www.vaxgen.com
- Host name: 86-105-245-69.haip.transip.net
- IP address: 86.105.245.69
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "VaxGen"
VaxGen - Wikipedia
VaxGen was a biopharmaceutical company based in the San Francisco Bay Area. Founded in 1995 and based in South San Francisco, California, the company was engaged in the development of vaccines that immunize against infectious disease, notably AIDS. On July 28, 2010, VaxGen Inc. was acquired by … See moreSee details»
VaxGen - Crunchbase Company Profile & Funding
VaxGen, Inc. operates as a biopharmaceutical company in the United States. It owns a biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that could be used to make cell culture or microbial biologic products.See details»
History of HIV Vaccine Research
VaxGen, Inc., Fighting the AIDS Epidemic
The VaxGen, Inc. case details the efforts of VaxGen and its president, Don Francis, to obtain approval to conduct phase III clinical trials in Thailand for AIDSVAX, an experimental vaccine …See details»
HIV gp120 Vaccine — VaxGen | Drugs in R&D - Springer
Nov 27, 2012 · VaxGen is developing prophylactic vaccines against HIV-1 consisting of two recombinant gp120 surface proteins from different HIV-1 strains.1 The bivalent vaccines [ …See details»
An HIV Vaccine — Challenges and Prospects - New …
Aug 28, 2008 · The initial empirical approach of immunizing with VaxGen's AIDSVax, a recombinant form of the outer glycoprotein-120 (gp120) portion of the HIV envelope, which was based on a strategy that was...See details»
AIDSVAX - Wikipedia
AIDSVAX is an experimental HIV vaccine that was developed originally at Genentech in San Francisco, California, and later tested by the VaxGen company, a Genentech offshoot. [1] . …See details»
Shares of AIDS Vaccine Maker Plummet - The New York Times
Feb 25, 2003 · VaxGen announced the results of its first large trial of the vaccine -- the first large one for any AIDS vaccine -- this morning. And while he saw some encouraging results, …See details»
AIDS Vaccine Development: Challenges and Opportunities
Jul 6, 2010 · The number of HIV vaccine researchers is now increasing, given the support of several organizations (e.g., Bill and Melinda Gates Foundation) and collaborations (e.g., …See details»
The Search for Effective HIV Vaccines | NEJM - New …
Aug 25, 2005 · In February 2003, after more than a decade of work, a team of scientists representing the biotechnology company VaxGen announced the results of the first phase 3 trial to test the efficacy of a...See details»
What Has 30 Years of HIV Vaccine Research Taught Us?
On the organizational side, the VaxGen results stimulated the search of mechanisms for a more strategic and coordinated approach to solve the HIV vaccine challenge. This led to the …See details»
Does VaxGen hide the breakthrough infections? - The Lancet
May 17, 2003 · According to VaxGen's report, after 5 years of trials, involving 5108 men who have sex with men and 309 women, all negative for HIV-1, the vaccine was ineffective. Commenting …See details»
Stanford Technology Ventures Program : The Vaxgen Story
Jan 28, 2004 · Genentech and Vaxgen have spent a total of 20 years and $300 million on developing the vaccine, says Francis, but there is still a long way to go. Francis discusses …See details»
40 years of AIDS vaccine research - IAVI
Dec 20, 2021 · Genentech spinoff VaxGen launches Phase III efficacy trial of AIDSVAX B/B, enrolling 5,400 volunteers, mostly MSM, in the U.S., Canada, the Netherlands, and Puerto …See details»
HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX …
VaxGen (formerly Genenvax) was formed as a spin-off company from Genentech with the sole purpose of developing the gp120 vaccine. VaxGen announced in July 2002 that the original …See details»
First HIV-1 vaccine in phase III trial - The Lancet
VaxGen's AIDSVAX consists of recombinant gp120 envelope antigens from two HIV-1 strains (figure). In earlier trials, AIDSVAX induced strong circulating antibody responses. Phase III …See details»
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection …
Dec 3, 2009 · In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections of a recombinant canarypox vector vaccine …See details»
AIDS Vaccine Results Draw Investor Lawsuits | Science - AAAS
VaxGen, the Brisbane, California, biotech that came under scientific fire last month when it revealed results of the first-ever real-world trial of an AIDS vaccine, is now dodging legal bullets.See details»
AIDS Vaccine Fails | Science - AAAS
Feb 24, 2003 · VaxGen says its vaccine helped prevent HIV infections in non-Caucasian trial participants. Data from the world's first full-scale, real-world test of an AIDS vaccine show that, …See details»
VaxGen's Sketchy Statistics | Science - AAAS
Feb 27, 2003 · But VaxGen scientists claimed that analyses revealed a statistically significant efficacy in 66.8% of blacks, Asians, and people of mixed race, and 78.3% in blacks alone.See details»